• Explore /
  • Poster
  • / Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).

Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).

Abstract Poster

Authors

null

Hui-Chuan Sun

Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

Hui-Chuan Sun , Xiao-Dong Zhu , Kui Wang , Hui Xue , Ning Yang , Ying-Cheng Yang , Yong-Jun Chen , Feng Ye , Ming Kuang , Shun-Li Shen , Cheng Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT05389527

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4120)

DOI

10.1200/JCO.2024.42.16_suppl.4120

Abstract #

4120

Poster Bd #

100

Abstract Disclosures

Similar Posters

First Author: Akihito Kawazoe

First Author: Ahmed Omar Kaseb

First Author: Elshad Hasanov

First Author: Lorenza Rimassa